the firm's post-grant practitioners are some of the most experienced in the country.

Craig R. Feinberg
Aldo  Martinez
Christopher  Ricciuti
Stephen G. Baxter, Ph.D.
Alexander B. Englehart
Diane  Jones
Aristotelis M. Psitos
Jenchieh (Joseph) Yuan
Tia D. Fenton
Jianping (James)  Wu
John F. Presper
Surinder  Sachar
Robert W. Downs
Daniel J. Pereira, Ph.D.
J. Derek  Mason, Ph.D., CLP
Brian B. Darville
Robert  Tarcu
Kurt M. Berger, Ph.D.
Steven B. Chang
Ching-Cheng (Tony)  Chang
Thomas M. Cunningham, Ph.D.
Carl E. Schlier
Akihiro  Yamazaki
Jay E. Rowe, Jr., Ph.D.
Long  Phan, Ph.D.
John  Sipos
Jeffrey B. McIntyre
Derek  Lightner, Ph.D.
Alec M. Royka
Ryan W. Smith
Yin Y. Nelson, Ph.D.
Stefan Uwe  Koschmieder, Ph.D.
Anna Z. Lloyd
Kevin M. McKinley
Erik M. Stang, Ph.D.
Yanwen  Fei
Chika (Teranishi) Iitoyo
Yuki  Onoe
Nanlin  Wang, Ph.D.
Frank J. West
Sameer  Gokhale
Grace E. Kim
James R. Love
Peifang  Tian, Ph.D.
Michael R. Casey, Ph.D.
Eric W. Schweibenz
Philippe J.C. Signore, Ph.D.
Charles L. Gholz
David M. Longo, Ph.D.
Bogdan A. Zinchenko
Johnny  Ma
Nicholas  Rosa, Ph.D.
Vincent K. Shier, Ph.D.
Colin B. Harris
John S. Kern
Maki  Saitoh
Elissa L. Sanford
Kevin L. Hartman, Ph.D.
Arthur I. Neustadt
Teddy S. Gron
Richard D. Kelly
Edwin D. Garlepp
Eckhard H. Kuesters
Dale M. Shaw
Tao  Feng, Ph.D.
Kevin Ross  Davis
Kasumi  Kanetaka
Andrew M. Ollis
Marina I. Miller, Ph.D.
Soumya  Panda
Yuanyi (Alex) Zhang, Ph.D.
Yorikatsu  Hohokabe, Ph.D.
Robert T. Pous
Christopher I. Donahue
Norman F. Oblon


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Increased Burden in Drafting "Surviving" and "Useful" Utility Patents in the Life Sciences Industry Extends to Design Patents

  • October 15, 2021
  • Article

Associated People

Associated Technologies

Patents are undoubtedly essential to many industries, and in recent years, the decisions regarding patent eligibility, written description, and enablement have certainly shaken up the life sciences industry in particular. There is an increasing burden on patent applicants and patentees to provide complex, lengthy, thoroughly written disclosures to satisfy the rising standards for written description and enablement, as well as the added pressure to draft multiple claims of varying scope.

Although it is well known that design patents can complement utility patents and play an important role in further protecting innovations, oftentimes design patents are overlooked. In contrast to utility patents, design patents protect the ornamental or nonfunctional features of a product – the claim is directed to the design embodied in or applied to the product, not the product itself. Unlike utility patents, design patents have no written description and are limited to one claim.

In a way, perhaps the law behind design patents may be relatively more simple and straightforward, and patent applicants would hope to skip the struggles of the meticulous process of drafting utility patent applications. However, a recent decision for a design patent in the life sciences industry indicates that design patent law is also developing.

Earlier this month, the Federal Circuit (CAFC) issued a decision in In re: SurgiSil, L.L.P. et al., No. 2020-1940 (Oct. 4, 2021). SurgiSil appealed a decision of the Patent Trial and Appeal Board (PTAB) affirming an examiner’s rejection of design patent application No. 29/491,550 (’550 application). The ’550 application claims an “ornamental design for a lip implant” and the application’s figure is shown below:

The examiner rejected the claim of the ’550 application as anticipated by an art tool called a stump, made of “tightly spiral-wound, soft gray paper” which is used “for smoothing and blending large areas of pastel or charcoal.” The “stump” is shown below:

The PTAB took the position that “it is appropriate to ignore the identification of the article of manufacture in the claim language.” However, the court agreed with SurgiSil’s argument that the “stump” could not anticipate the claim, because the stump is a “very different” article of manufacture than a lip implant. The court held that the relevant test for applicable prior art for the claim at issue is limited to the particular “article of manufacture” identified in the claim. Because the claim of the ’550 application identified a lip implant, and the application’s figure depicted a lip implant, the claim is limited to lip implants and does not cover other articles of manufacture.

Therefore, the claim language of a design patent can certainly limit the claim scope to the article manufacture recited in the claim, both when evaluating for an anticipation rejection during prosecution, and at the alternative end, when evaluation for infringement during litigation. This decision highlights the recent trend in both utility patents and design patents alike, that the applicant must take careful considerations when drafting the application. For example, just as clear and sufficient written description must be provided in utility patents, design patents should properly title and identify the article of manufacture. Using a similar strategy as for drafting multiple claims of varying scope in utility patents, design patent applicants should also consider filing multiple, separate design patent applications for the same design, identifying different articles of manufacture and claims, to increase the scope of protection for the design.

The good news for design patents is that unlike for utility patents in the life sciences industry where prosecution has become more challenging and the threat of patents being invalidated based on issues such as lack of written description and enablement has amplified, it may be easier to prosecute a design patent application, and perhaps harder to invalidate a design patent based on prior art, as the prior art must be for the same article of manufacture. Nevertheless, it remains to be seen how this decision influences how design patents are claimed in the future, and how the USPTO reacts to these changes.